Search

Displaying results 2071 - 2080 of 10000 in total
  1. Drug

    Regadenoson

    go.drugbank.com/drugs/DB06213
    ApprovedInvestigational

    Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.

    Categories: Adenosine A receptor agonists, Adenosine A2 Receptor Agonists
  2. Drug

    Metergoline

    go.drugbank.com/drugs/DB13520
    Approved

    [A27181] Its use has been studied in various clinical settings such as a treatment for seasonal affective disorder, prolactin hormone regulation due to its inhibitory effect on prolactin release,[A27182 … Metergoline is an antagonist at various 5-HT receptor subtypes at a relatively low concentration and agonist at dopamine receptors.

  3. Drug

    Natalizumab

    go.drugbank.com/drugs/DB00108
    ApprovedInvestigational

    Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin.

  4. Drug

    Medifoxamine

    go.drugbank.com/drugs/DB13219
    Approved

    Medifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity

  5. Drug

    Dronedarone

    go.drugbank.com/drugs/DB04855
    ApprovedInvestigational

    [T28] Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009. … A safety concern for the risk of drug-induced hepatocellular injury has been issued following marketing of dronedarone.[L8800]

    Categories: Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  6. Drug

    Ceruletide

    go.drugbank.com/drugs/DB00403
    Approved

    It exerts stimulatory effects on the gastric, biliary, and pancreatic secretion, as well as on certain smooth muscles. … Caerulein is a specific decapeptide similar in action and composition to the natural gastrointestinal peptide hormone cholecystokinin.

  7. Drug

    Amifampridine

    go.drugbank.com/drugs/DB11640
    Approved

    Amifampridine phosphate is a more stable salt that serves as an active ingredient of EMA-approved Firdapse, which was previously marketed as Zenas. … It is currently used as the first-line symptomatic treatment for LEMS in adult patients and is ideally given as oral tablets in divided doses, three or four times a day.

  8. Drug

    Anthoxanthum odoratum

    go.drugbank.com/drugs/DB14163
    Approved

    Anthoxanthum odoratum allergenic extract is used in allergenic testing.

    Products: Standardized Grass Pollen - Sweet Vernal Grass (10,000 Bau/ml)
  9. Drug

    Ribociclib

    go.drugbank.com/drugs/DB11730
    ApprovedInvestigational

    Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6).

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  10. Drug

    Ixazomib

    go.drugbank.com/drugs/DB09570
    ApprovedInvestigational

    [L51244] It was also investigated in other hematological malignancies as well as other conditions, such as systemic light chain (AL) amyloidosis, graft-versus-host disease, and lupus nephritis. … Ixazomib is a reversible proteasome inhibitor. Because it is a modified peptide boronic acid with one chiral center,[A264329] it is considered a boronate proteasome inhibitor.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index